Phase 2 drug target engagement study of PLN-74809 in patients with idiopathic pulmonary fibrosis using a novel αvβ6 cystine knot PET imaging tracer2236 Introduction: Molecular imaging holds great potential to advance our understanding of pulmonary fibrosis and accelerate the development of novel ...
之前在关注名单里排第二 Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholan…
Phase 1 studies of PLN-74809 in healthy volunteers have demonstrated good oral bioavailability and tolerability with a t1/2 supportive of once daily dosing.Inhibition of αVβ6-mediated TGF-β activation in the lung by can be detected through measurement of SMAD phosphorylation in alveolar ...
Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis译:姚佳思 校:曹文东本文来自罕见病信息网团队。欢迎转发分享;媒体、网站等平台如需转载,须注明来源。如有其他合作需求,请发送邮件至:info@cord.org.cn。